University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Sabrina M. Ronen, PhD

Sabrina M. Ronen, PhD

Professor in Residence, Department of Radiology, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

The goal of studies performed in my laboratory is to identify validated translational magnetic resonance spectroscopy (MRS) metabolic biomarkers of oncogenic transformation and response to existing and emerging anti-cancer therapeutics.

I am a Professor in the Department of Radiology and Biomedical Imaging at UCSF, a member of UCSF Brain Tumor Center and the Developmental Therapeutics Program at the UCSF HDFCCC, and a member of the California Institute for Quantitative Biosciences (QB3). I have an international track record using MRS in preclinical models of cancer to investigate cellular metabolism, and to identify and mechanistically validate novel MRS-based biomarkers. Our studies use established and engineered cell lines and animal models; multinuclear MRS approaches, including thermal equilibrium and hyperpolarized 13C MRS, 31P MRS and 1H MRS; and a range of biochemical, cell, and molecular biological assays, and our major focus is the study of brain tumors.

Current funded projects in the lab, in collaboration with members of the HDFCCC, the Brain Tumor Center, and the Developmental Therapeutics Program, focus on understanding the metabolic reprogramming of mutant IDH tumors and its significance for therapeutic targeting, metabolic imaging of response to targeted therapies in sensitive and resistant models, and imaging of response to emerging immunotherapies.

Education

Hebrew University, Israel, BSc, 1981, Chemistry/Biochemistry
San Jose State University, California, MS, 1986, Chemistry
Weizmann Institute of Science, Israel, PhD, 1991, Chemical Physics


Professional Experience

  • 1978-1981
    Laboratory Assistant, Hebrew University, Biochemistry Department, Israel
  • 1981-1984
    Assistant Staff, Raychem Corporation, Polymer Manufacturing R&D, Menlo Park, California
  • 1985-1986
    M.Sc., student, San Jose State University, San Jose, California
  • 1987-1992
    Ph.D., student, Weizmann Institute of Science, Israel
  • 1992-1994
    INSERM Poste Vert Visiting Researcher, Institut Curie, Cancer Research Inst., Paris, France
  • 1994-1996
    British Heart Foundation Fellow, Harefield Hospital Nephrology Department, Harefield, UK
  • 1996-2003
    ICR fellow and leader, Pre-clinical Cellular Processes Team, CRUK Clinical Magnetic Resonance Research Group, Institute of Cancer Research Sutton, Surrey, UK
  • 2004-2007
    Associate Professor, Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas
  • 2007-2012
    Associate Professor, Department of Radiology, UCSF, San Francisco, California
  • 2012-present
    Professor in Residence, Department of Radiology, UCSF, San Francisco, California

Honors & Awards

  • B.Sc. cum laude
  • Recipient of the Eshkol scholarship for Ph.D. studies
  • Recipient of an ICR fellowship (first three years at Institute at Institute of Cancer Research, UK)
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary Elect 2006
  • International Society for Magnetic Resonance in Medicine (ISMRM) MR in Cancer Study Group - Secretary 2007

Selected Publications

  1. Chung BT, Chen HY, Gordon J, Mammoli D, Sriram R, Autry AW, Le Page LM, Chaumeil M, Shin P, Slater J, Tan CT, Suszczynski C, Chang S, Li Y, Bok RA, Ronen SM, Larson PEZ, Kurhanewicz J, Vigneron DB. First hyperpolarized [2-13C]pyruvate MR studies of human brain metabolism. J Magn Reson. 2019 Oct 08; 309:106617.
    View on PubMed
  2. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep. 2019 Jul 19; 9(1):10521.
    View on PubMed
  3. Majumdar S, Lupo J, Vigneron D, Ronen S, Kurhanewicz J, Hess C. In memoriam: Sarah J. Nelson, January 26, 1954-April 3, 2019. Magn Reson Med. 2019 Oct; 82(4):1255-1258.
    View on PubMed
  4. Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM. In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Sci Rep. 2019 Mar 04; 9(1):3402.
    View on PubMed
  5. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed. 2019 02; 32(2):e4044.
    View on PubMed
  6. Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, Zhang X, Malloy CR, Rizi R. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia. 2019 01; 21(1):1-16.
    View on PubMed
  7. Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR. Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI. Chem Commun (Camb). 2018 May 17; 54(41):5233-5236.
    View on PubMed
  8. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3.
    View on PubMed
  9. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Res. 2018 05 01; 78(9):2290-2304.
    View on PubMed
  10. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10743-10748.
    View on PubMed
  11. Guglielmetti C, Najac C, Didonna A, Van der Linden A, Ronen SM, Chaumeil MM. Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6982-E6991.
    View on PubMed
  12. Roy S, Leidal AM, Ye J, Ronen SM, Debnath J. Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake. Mol Cell. 2017 Jul 06; 67(1):84-95.e5.
    View on PubMed
  13. Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 03 22; 7:44792.
    View on PubMed
  14. Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, Yagnik G, Wagner JR, De Lay M, Carrera D, Castro BA, Hayes J, Sidorov M, Garcia JLI, Eriksson P, Ronen S, Phillips J, Molinaro A, Koliwad S, Aghi MK. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017 01 26; 2(2):e88815.
    View on PubMed
  15. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689.
    View on PubMed
  16. Najac C, Ronen SM. MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Top Magn Reson Imaging. 2016 Oct; 25(5):187-196.
    View on PubMed
  17. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 08 10; 6:31397.
    View on PubMed
  18. Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 10; 14(10):976-983.
    View on PubMed
  19. Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 12:180-9.
    View on PubMed
  20. Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 07; 7(23):34942-55.
    View on PubMed

Go to UCSF Profiles, powered by CTSI